Tinzaparin Sodium

Quick links

Choose a section

Quick links to important sections

Advertisements

Tinzaparin Sodium

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Tinzaparin Sodium

What is Tinzaparin Sodium?

Tinzaparin sodium is a medication classified as a low molecular weight heparin (LMWH). It is a biological substance derived from porcine (pig) intestinal mucosa that undergoes a specific manufacturing process to create shorter chains of heparin molecules. This structural characteristic allows the medication to have a more predictable effect on the body's blood-clotting mechanisms compared to standard, unfractionated heparin.

Mechanism of Action

Tinzaparin sodium functions as an anticoagulant, often referred to as a blood thinner. It works by enhancing the activity of antithrombin III, a naturally occurring protein in the blood that inhibits clotting factors. Specifically, tinzaparin has a high affinity for inhibiting Factor Xa, an enzyme that plays a critical role in the coagulation cascade. By slowing down the chemical reactions that lead to the formation of fibrin, the medication helps prevent the blood from forming solid clots.

Primary Uses

This medication is primarily utilized in the management and prevention of thromboembolic disorders, which are conditions characterized by the formation of blood clots within the vascular system. Common applications include:

  • Deep Vein Thrombosis (DVT): The formation of a blood clot in a deep vein, usually in the legs.
  • Pulmonary Embolism (PE): A condition where a blood clot travels to the lungs, often originating from a DVT.

Because of its anticoagulant properties, tinzaparin sodium is used to treat existing clots by preventing them from growing larger, which allows the body to naturally break them down over time. It is also used prophylactically in certain clinical settings to reduce the risk of new clots forming in patients who are considered at high risk.

Advertisements

What side effects are possible with Tinzaparin Sodium?

Possible side effects and safety information

The safety profile of Tinzaparin Sodium is defined by its function as an anticoagulant, with official regulatory documents detailing a range of adverse reactions classified by frequency and system-organ class.

Adverse Reaction Frequencies

Side effects documented in regulatory labeling are classified as follows:

  • Common (1/100 to < 1/10): Haemorrhage (bleeding events), Injection site reactions (e.g., pain, haematoma, pruritus), and Anaemia.
  • Uncommon (1/1,000 to < 1/100): Thrombocytopenia (Type I), Increased hepatic enzymes (e.g., ALT, AST), Hypersensitivity, and Rash.
  • Rare (1/10,000 to < 1/1,000): Heparin-induced thrombocytopenia (HIT Type II, immune-mediated), Anaphylactic reaction, Skin necrosis, and Osteoporosis (associated with long-term use).

Serious Adverse Reactions and Safety Constraints

Officially documented serious adverse reactions include Major Haemorrhage and the rare but severe events of Spinal/Epidural Haematoma and Anaphylactic Reaction. Tinzaparin Sodium is contraindicated in the presence of confirmed or suspected immune-mediated HIT Type II or active major bleeding. The medication must not be administered by intramuscular (IM) injection due to the risk of haematoma formation.

Population-Specific Safety Notes

The official label contains specific safety notes for certain populations. The effects of Tinzaparin Sodium may be increased in patients with severe renal impairment due to reduced clearance. For pediatric patients, multi-dose vials containing benzyl alcohol as a preservative are officially contraindicated in children under 3 years old, premature infants, and neonates.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official overdose information for Tinzaparin Sodium focuses exclusively on the signs of excessive anticoagulation and mandated emergency actions. All statements are derived from authoritative government regulatory documents.

Property Official Regulatory Statement
Documented Overdose Presentations The principal manifestation of overdosage is the exaggerated pharmacological effect, which is bleeding or hemorrhage. Specific signs of excessive bleeding include unusual bruising, black or bloody stools, blood in the urine, bleeding gums, and pinpoint red spots on the skin.
Severe Outcomes & Help Required Overdose may lead to major hemorrhage in critical organs or a spinal/epidural hematoma with the potential for paralysis. For any sign of major hemorrhage or neurological symptoms (e.g., back pain, motor deficits, bowel or bladder dysfunction), official guidance requires the patient to seek immediate medical attention.
Antidote and Monitoring Protamine sulfate is the documented reversal agent capable of partially neutralizing the anticoagulant effects. Close and frequent monitoring of the patient is required to detect any signs of neurological injury.
Population-Specific Notes The drug’s effects may be increased in patients with kidney disease due to slower removal from the body. An increased risk for death is noted for elderly patients with renal insufficiency.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile based on the primary, dose-dependent risk of hemorrhage, which can escalate to major or life-threatening hemorrhage. This profile mandates seeking immediate medical help upon observation of specific bleeding signs or symptoms of neurological injury that may indicate a serious hematoma. Official management involves the documented use of the specific reversal agent, Protamine sulfate, and emphasizes the increased risk for individuals with renal impairment.

Advertisements

Therapeutic Uses of Tinzaparin Sodium

What Tinzaparin Sodium Treats: Main Uses and Benefits

Tinzaparin sodium is a prescription medication used to address certain conditions. Its primary use involves the management and prevention of conditions characterized by blood clot formation in the blood vessels, falling within the therapeutic domain for the management and prophylaxis of venous thromboembolism (VTE). This medication is commonly used to help with reducing the likelihood of blood clot formation in patients undergoing surgery or experiencing limited mobility due to acute medical illness.

This medication is considered relevant for the management of acute episodes of deep vein thrombosis (DVT) and pulmonary embolism (PE), and is also used in contexts where preventative symptom management is applied. Clinical indications include the treatment of deep vein thrombosis and/or pulmonary embolism, and the prevention of VTE associated with certain surgical or medical circumstances. It may be part of symptomatic management in clinical settings involving haemodialysis.

Overall, this medication may assist with maintaining a sense of stability during periods of heightened symptoms and physiological stress. It supports patients during episodes of heightened discomfort.

“This agent is used in areas where short-term symptom management is appropriate.”


Quick Fact: Relief for symptoms related to systemic imbalance


Regulatory References

  1. Product Monograph including Patient Medication Information PrINNOHEP® tinzaparin sodium Sterile solution for subcutaneous (SC)
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Tinzaparin Sodium?

Eligibility for Tinzaparin Sodium is strictly defined by regulatory bodies based on age, specific medical conditions, and other population factors, as outlined in official labeling.


Populations Who Must Not Use (Contraindications)

Condition / History Restriction Type
Heparin-Induced Thrombocytopenia (HIT) Absolute Contraindication
Active Major Hemorrhage Absolute Contraindication
Acute Septic Endocarditis Absolute Contraindication
Hypersensitivity to heparin, Tinzaparin, or excipients Absolute Contraindication
Neonates/Premature Infants (if using multi-dose vial) Absolute Contraindication

Populations Requiring Restriction or Caution

Population / Condition Eligibility Status
Pediatric Population (under 18 years) Use Not Established (Insufficient Data)
Severe Renal Impairment (CrCl < 30 ml/minute) Use Not Recommended
Geriatric Patients Caution Advised (due to potential renal decline)
Pregnancy (near term, multi-dose vial only) Contraindicated (due to benzyl alcohol)

Tinzaparin Sodium is generally approved for use in adults (18 years and older). While it can be used during pregnancy and breastfeeding when clinically necessary, the preservative-free formulation is the preferred choice to avoid exposure to benzyl alcohol.

Advertisements

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Tinzaparin Sodium based on documented pharmacodynamic effects and specific co-administration constraints.

Medicinal Product Categories

The principal documented interaction involves pharmacodynamic reinforcement with other medicines that affect hemostasis, which may increase the risk of bleeding. These include other oral anticoagulants, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), platelet inhibitors, and thrombolytic agents. A separate pharmacodynamic caution exists for Potassium-Elevating Drugs (such as ACE inhibitors), as the combination may heighten the risk of hyperkalemia due to the reported suppression of aldosterone. No established interactions with food or herbal products are officially documented.

Procedural and Population Constraints

Specific procedural restrictions are mandated in the label: Intramuscular injections must be strictly avoided due to hematoma risk. Therapeutic doses are contraindicated with neuraxial anaesthesia, and timing separation rules (e.g., minimum 12-hour pre-procedure delay) must be followed for prophylactic use near spinal/epidural procedures. Severe renal impairment (creatinine clearance < 30 mL/min) is noted as a condition leading to reduced clearance of Tinzaparin. The excipient benzyl alcohol in multi-dose vials is contraindicated for use in neonates and infants.

Advertisements

Mechanism of Action

Targeted Potentiation of Antithrombin

Tinzaparin Sodium produces its anticoagulant action through the potentiation of a natural plasma protease inhibitor, Antithrombin (AT), leading to selective enzyme inhibition within the coagulation cascade. The core mechanism begins when Tinzaparin binds to AT, immediately accelerating AT's intrinsic ability to neutralize activated clotting enzymes by a factor of over 1,000. This molecular interaction acts as a catalyst, accelerating the inhibitory function of a pre-existing plasma system.

Selective Inhibition of Factor Xa

The potentiated Antithrombin-Tinzaparin complex preferentially targets and rapidly inactivates Factor Xa (FXa), an enzyme essential for converting Prothrombin into Thrombin. By inhibiting this pivotal step, the drug effectively blocks the downstream production of Thrombin at its source. Tinzaparin exhibits low activity against Thrombin (Factor IIa) itself due to its shorter molecular chain length, which functionally constrains its ability to bridge AT to Thrombin.

Constraint on Fibrin Clot Formation

The resulting sharp decrease in available active Thrombin curtails the final, essential step of coagulation: the conversion of soluble Fibrinogen into the insoluble Fibrin mesh. This molecular constraint decreases the formation and structural stability of a thrombus. The physiological consequence is suppressed thrombus propagation, resulting from reduced Thrombin activity and limited Fibrin generation.

Advertisements

Dosage and Administration Information

Administration Overview

Tinzaparin sodium is a low molecular weight heparin (LMWH) administered via subcutaneous injection. This method involves delivering the medication into the fatty tissue layer located just beneath the skin. Proper administration is essential to ensure the medication is absorbed correctly into the systemic circulation.

Preparation for Use

Before the medication is used, the pre-filled syringe should be inspected for any particulate matter or discoloration. The solution should appear clear and colorless to pale yellow. The protective needle cap is removed only when the individual is ready to perform the injection. Air bubbles present in the syringe should not be expelled prior to injection unless specifically required by the concentration, as the bubble helps ensure the full dose is delivered.

Injection Site Selection

Common sites for subcutaneous injection include the abdomen, usually at least two inches away from the navel, or the outer aspects of the thighs. It is standard practice to rotate injection sites between the left and right sides of the body with each subsequent dose to minimize the risk of localized skin irritation or tissue changes.

Technique for Subcutaneous Injection

The procedure generally involves the following steps:

  • Skin Preparation: The chosen injection site is typically cleaned with an alcohol swab and allowed to air dry.
  • Positioning: The individual should be in a comfortable position, such as sitting or lying down, where the injection site is easily accessible.
  • Skin Fold: A fold of skin is gently pinched between the thumb and forefinger to lift the fatty tissue away from the underlying muscle.
  • Insertion: The needle is inserted at a 90-degree angle (perpendicular) into the skin fold.
  • Injection: The plunger is depressed steadily until the entire volume of the syringe has been discharged.
  • Withdrawal: The needle is removed directly, and the skin fold is released.

Post-Injection Care

Following the withdrawal of the needle, light pressure may be applied to the site with a clean gauze pad if necessary. To prevent bruising or localized hematoma, the injection site should not be rubbed or massaged after the medication has been delivered. Used syringes and needles are disposed of in a puncture-resistant sharps container.

Advertisements

Recent Clinical Evidence

Tinzaparin sodium is a low molecular weight heparin (LMWH) primarily used as an anticoagulant for the prevention and treatment of blood clots. Research has focused on its use in venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).


Efficacy in Acute VTE

Clinical trials have investigated the role of once-daily subcutaneous tinzaparin compared to unfractionated heparin (UFH) for treating acute, symptomatic DVT, with or without PE. Study findings suggest that tinzaparin is comparable in effectiveness to UFH, while offering the advantage of once-daily dosing without the need for routine laboratory monitoring in clinically stable patients. This predictability stems from its pharmacokinetic profile, which allows for consistent anticoagulant activity.


Specialized Clinical Populations

Cancer-Associated Thrombosis (CAT)

Research has explored the use of LMWHs, including tinzaparin, for the treatment of VTE in patients with cancer. Studies examining extended tinzaparin therapy (up to six months) for CAT have reported its efficacy and safety profile to be favorable compared to vitamin K antagonists (e.g., warfarin) for reducing the risk of VTE recurrence.

Renal Impairment

Tinzaparin has been investigated in individuals with decreased kidney function. Clinical data suggest that, compared to some other LMWHs, tinzaparin exhibits a potentially lower risk of drug accumulation in patients with moderate renal impairment. However, patients with severe renal impairment require careful clinical consideration and monitoring, as clearance of the drug may be reduced.

Key Studies & References

  1. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients (Key CAT trial protocol/findings)
  2. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function - Thieme Connect (Comparative accumulation study in elderly/RI)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tinzaparin Sodium (FAQ)


Q: How is Tinzaparin Sodium different from Enoxaparin (Lovenox)?

Both Tinzaparin Sodium and Enoxaparin are classified as Low Molecular Weight Heparins (LMWHs), meaning they work similarly to prevent blood clots. However, official labeling states these products are not interchangeable and should not be substituted for one another.


Q: How long does Tinzaparin Sodium stay in your system?

The time Tinzaparin Sodium stays in the body is estimated by its elimination half-life, which indicates how long it takes for half of the anti-clotting activity to be removed. Official pharmacokinetic data indicates that the elimination half-life is approximately 3 to 4 hours after the subcutaneous injection.


Q: How quickly does Tinzaparin Sodium start working after the first injection?

The anti-clotting effect of Tinzaparin Sodium begins relatively quickly after administration. Official product information shows that blood levels of anti-Factor Xa activity typically begin to rise within the first 2 to 3 hours and reach their peak concentration within 4 to 5 hours after the injection.


Q: What happens if I miss a dose of Tinzaparin Sodium?

Regulatory guidance advises patients who miss a dose to contact their healthcare provider for instructions right away. If you miss a dose, you should never double your next dose to make up for the one you skipped. Official guidance advises patients to contact their healthcare provider for instructions.


Q: Can Tinzaparin Sodium cause unusual bruising?

As an anticoagulant, Tinzaparin Sodium affects blood clotting. Official reports include bleeding-related issues; bruising or ecchymosis (skin discoloration from bleeding) is listed as an uncommon side effect. Any new or unusual bruising should be discussed with a healthcare provider.


Q: Can children or teenagers be prescribed Tinzaparin Sodium?

Official regulatory documents state that the safety and effectiveness of Tinzaparin Sodium have not been established in pediatric patients (those under 18 years of age). Furthermore, multi-dose vials containing the preservative benzyl alcohol are specifically contraindicated for use in newborns and premature infants.


Q: What is the usual length of treatment with Tinzaparin Sodium?

The length of treatment varies depending on the specific medical reason for its use. For treating an acute clot (like DVT), the course of therapy is typically for a minimum of 6 days. For preventative treatment (prophylaxis) post-surgery, treatment may continue for about 7 to 10 days.


Q: Does Tinzaparin Sodium need to be stored in the refrigerator?

No, Tinzaparin Sodium should be stored at room temperature, typically below 30 C (or 86 F). It is critical to keep the medicine from freezing and protect it from excessive heat and direct light.


Q: Can Tinzaparin Sodium be used for people with kidney problems?

Official information advises caution for patients with kidney problems because the drug's clearance may be reduced. Use is generally not recommended for individuals with severe renal impairment (a very low creatinine clearance) unless the dose can be closely monitored by a healthcare professional.


Q: What is the best time of day to take Tinzaparin Sodium?

Official labeling advises that Tinzaparin Sodium is administered once daily via subcutaneous injection. While a specific time of day is not mandated, it is generally recommended in the labeling to take the injection at approximately the same time each day to maintain consistent blood levels.


Q: Are headaches a known side effect of Tinzaparin Sodium?

Yes, official regulatory documents and clinical trial information often list headache as a common side effect associated with Tinzaparin Sodium use. Any persistent or severe headaches should be discussed with a healthcare provider.


Q: What foods or drinks should I limit while taking Tinzaparin Sodium?

The official product labeling for Tinzaparin Sodium states that there are no established interactions with food or herbal products. This differs from some other anticoagulants, but you should still inform your prescriber of all supplements you take.


Q: Does Tinzaparin Sodium interact with herbal supplements?

Official regulatory documents state that there are no established interactions between Tinzaparin Sodium and herbal products. However, due to the general bleeding risk, it is still advisable to inform your healthcare provider about any herbal supplements you take.


Q: Is it okay to drink alcohol in moderation while on this medication?

The official labeling for Tinzaparin Sodium does not provide specific guidance regarding alcohol consumption. Because the drug works to reduce blood clotting, caution is advised, and any concerns about alcohol consumption should be discussed with a healthcare provider.


Q: How should I dispose of the used Tinzaparin needles?

Used syringes and needles must be immediately placed in a designated, puncture-resistant sharps disposal container. This container should then be securely closed and kept out of the reach of children. Local authority guidelines should be followed for the safe disposal of the full container.


Q: What happens if Tinzaparin Sodium is accidentally injected incorrectly?

The medicine is strictly intended for subcutaneous use and must not be administered into the muscle (intramuscularly). Use by an incorrect route could increase the risk of bleeding or bruising due to the nature of the medication.


Q: Is Tinzaparin Sodium used for treating existing blood clots or only preventing new ones?

According to the official indications, Tinzaparin Sodium is approved for both purposes. It is used for the treatment of acute blood clots, such as Deep Vein Thrombosis (DVT), and for the prophylaxis (prevention) of blood clots in at-risk patients.


Q: Are there long-term side effects associated with Tinzaparin Sodium use?

While the drug is typically used for defined periods, official safety information indicates that the rare side effect of Osteoporosis (a condition causing weak bones) is associated with long-term treatment with Tinzaparin Sodium.


Q: Can Tinzaparin Sodium cause a temporary drop in platelet count?

Yes, official safety data lists Thrombocytopenia (Type I), which is a temporary drop in the platelet count, as an uncommon side effect of Tinzaparin Sodium.


Q: Is it normal to feel tired or fatigued when taking Tinzaparin Sodium?

While feeling tired or fatigued is not listed among the most common adverse reactions, it has been reported in clinical settings. Any persistent or unusual tiredness should be discussed with a healthcare provider.


Q: Is Tinzaparin Sodium the same drug as Fragmin?

No, Tinzaparin Sodium (Innohep) and Fragmin (Dalteparin) are different Low Molecular Weight Heparin medications. Official bodies advise that these products are not interchangeable and have distinct pharmacokinetic profiles.


Q: Do I need to change my diet while I'm on Tinzaparin Sodium?

The official product labeling indicates that there are no known established interactions between Tinzaparin Sodium and food. Unlike some other anticoagulants, a specific diet change is not usually required.


Q: What should I tell a new doctor about my Tinzaparin Sodium use?

It is important to inform any new healthcare provider that you are currently taking Tinzaparin Sodium. Critical medical history points to mention include a history of bleeding problems, severe kidney impairment, and any past reaction like Heparin-Induced Thrombocytopenia (HIT).


Q: How do I recognize an allergic reaction to Tinzaparin Sodium?

If signs of a severe allergic reaction occur, immediate medical attention should be sought. These signs may include sudden difficulty breathing, swelling of the face, lips, or tongue, or a severe, spreading rash. Other types of hypersensitivity reactions are listed as uncommon.


Q: Is there a reversal agent for Tinzaparin Sodium if a major bleed occurs?

Yes, in the event of a severe bleeding episode or suspected overdose, the anticoagulant effect can be partially inhibited by administering Protamine Sulfate, as stated in the product monograph.


Q: Is it common to feel nauseous after injecting Tinzaparin Sodium?

Official adverse event reports include nausea and vomiting as reported side effects. If you experience these symptoms consistently, they should be discussed with your healthcare provider.


Q: Why are people sometimes prescribed Tinzaparin Sodium for a few weeks only?

The medicine is often prescribed for short, specific periods to manage a temporary risk, such as preventing blood clots following major surgery. Official dosing information for VTE prophylaxis (prevention) post-surgery typically lasts between 7 to 10 days or until the patient's mobility improves.

Advertisements

How should Tinzaparin Sodium be stored and disposed of?

Tinzaparin sodium must be stored in a closed container at room temperature, and this temperature must not exceed 30°C. It is mandatory to keep the product from freezing and protect it from heat, moisture, and direct light.

After a multi-dose vial is first opened, its in-use stability is defined as 28 days at 30°C. The solution should be inspected for particles or cloudiness before use, and any visually degraded product or outdated medicine must be discarded.

The medicine must be kept out of the reach of children.

Unused medicinal product and waste material must be disposed of in accordance with local requirements. Used syringes and needles must be placed in a puncture-resistant container, commonly called a sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tinzaparin Sodium found in:

A-Z Index: